↑Snyder JA, "Pharmaceutical compositions and methods utilizing substituted bicyclo[2.2.2]-octanes", US patent 3362878, issued 9 January 1968, assigned to EIDP Inc.
↑"Inhibition of amine uptake by 4-phenyl-bicyclo(2,2,2)octan-1-amine hydrochloride monohydrate (EXP 561) in rats". biochemical Pharmacology25 (21): 2409–2410. November 1976. doi:10.1016/0006-2952(76)90039-3. PMID999731.
↑"Blockade of monoamine uptake by 1-amino-4-phenylbicyclo(2,2,2)octane (EXP 561) in rat brain and heart". Neuropharmacology16 (1): 11–15. January 1977. doi:10.1016/0028-3908(77)90040-5. PMID834358.
↑ 5.05.1"Pharmacological properties of EXP 561, a potential antidepressant drug". Journal of Neural Transmission70 (1–2): 81–97. 1987. doi:10.1007/BF01252511. PMID2822850.
↑Snyder JA, "4-Phenylbicyclo[2.2.2]octane-1-amines and salts thereof", US patent 3308160, issued 7 March 1967, assigned to EIDP Inc.
↑"A clinical-pharmacological study with EXP 561". Current Therapeutic Research, Clinical and Experimental9 (6): 306–308. June 1967. PMID4963065.
↑"Non-correlation of preclinical-clinical evaluation of a prosposed anti-depressant 4-phenyl-bicyclo(2,2,2)octan-1-amine hydrochloride monohydrate (EXP 561)". Arzneimittel-Forschung18 (2): 243–245. February 1968. PMID5695389.
↑"Inhibition of 3H-dopamine accumulation in reserpinized and normal rat striatum". Acta Pharmacologica et Toxicologica44 (5): 329–335. May 1979. doi:10.1111/j.1600-0773.1979.tb02339.x. PMID474143.
↑"[Phenylcyclohexylamine and derivatives. IV. Salts of trans-4-phenylcyclohexylamine with -substituted 4-diphenyl- and 4-cyclohexylphenyl acetic acids and their pharmacological activity]". Il Farmaco; Edizione Scientifica28 (4): 265–277. 1973. PMID4698884.